Differentiating chronic myelogenous leukemia in primary blast crisis (CML-BC) from de novo <i>BCR-ABL1</i>-positive acute myeloid leukemia (AML) is a diagnostic challenge with therapeutic consequences. This evidence concerns the gene ABL1 and breast cancer.